Search
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.
Edodekin alfa
go.drugbank.com/drugs/DB15631Investigationalinvestigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by
Talnetant
go.drugbank.com/drugs/DB06429InvestigationalTalnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Betulinic Acid
go.drugbank.com/drugs/DB12480ApprovedWithdrawnBetulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSPRTX-100
go.drugbank.com/drugs/DB05947InvestigationalThese binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system. … PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases
Ouabain
go.drugbank.com/drugs/DB01092ApprovedIt is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
BLX-883
go.drugbank.com/drugs/DB05904InvestigationalBLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C.
NSI-566
go.drugbank.com/drugs/DB17954InvestigationalDeveloped by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]
Drozitumab
go.drugbank.com/drugs/DB19106InvestigationalIt was developed by Genentech as a drug for the treatment of cancers
(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalWarfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.